POTS Subtypes: Which One Do You Have?

POTS is not a single disease. It is a syndrome — a collection of symptoms with a common final pathway (excessive heart rate increase on standing) that can arise from multiple distinct underlying mechanisms. Identifying your POTS subtype is not just an academic exercise: different subtypes respond to different treatments, and the wrong treatment can make symptoms worse.

The Four Main Subtypes

1. Neuropathic POTS (Partial Dysautonomic POTS)

Mechanism: Damage to or dysfunction of the small autonomic nerve fibers that control blood vessel constriction in the lower extremities. Blood pools in the legs because the nerves that should constrict leg blood vessels on standing are not working properly.

Key features: Normal or mildly elevated standing norepinephrine (200–500 pg/mL), reduced sweat output on QSART, possible reduced intraepidermal nerve fiber density on skin biopsy, often associated with small fiber neuropathy symptoms (burning feet, numbness).

Best treatments: Midodrine (vasoconstrictor), pyridostigmine, compression garments, high sodium/fluids, IVIG if autoimmune cause confirmed.

2. Hypovolemic POTS (Low-Flow POTS)

Mechanism: Chronically reduced circulating blood volume, making the cardiovascular system unable to compensate for orthostatic blood pooling.

Key features: Often a relatively high hematocrit, dramatic improvement with IV saline, low aldosterone or impaired RAAS activity, responds well to volume expansion.

Best treatments: High sodium intake (up to 10,000 mg/day), fludrocortisone, IV saline infusions, compression garments, exercise reconditioning.

3. Hyperadrenergic POTS

Mechanism: Excessive sympathetic nervous system activation on standing, producing a surge in norepinephrine that causes tachycardia alongside hypertension, tremor, and anxiety-like symptoms.

Key features: Standing norepinephrine ≥600 pg/mL, blood pressure often rises on standing, tremor, profuse sweating, anxiety/panic-like episodes, often worsens with standard beta-blocker doses.

Best treatments: Clonidine, very low-dose beta-blockers, MCAS treatment if mast cells are driving the norepinephrine surges. Avoid fludrocortisone and midodrine.

4. Autoimmune POTS

Mechanism: Autoantibodies against autonomic receptors (ganglionic acetylcholine receptors, adrenergic receptors, muscarinic receptors) impair autonomic nerve signaling.

Key features: Positive autoantibody testing, often post-infectious or post-vaccination onset, may have other autoimmune markers (elevated ANA, inflammatory markers), can overlap with neuropathic subtype.

Best treatments: IVIG, plasmapheresis, rituximab, low-dose naltrexone, immunosuppressants.

Overlap and Mixed Subtypes

Many patients have features of more than one subtype. The most common combinations are:

• Neuropathic + hypovolemic: Nerve damage impairs vasoconstriction AND blood volume is low — both problems compound each other
• Hyperadrenergic + MCAS: Mast cell mediators drive norepinephrine surges — treating MCAS often dramatically improves the hyperadrenergic component
• Autoimmune + neuropathic: Autoimmune damage to autonomic nerve fibers produces neuropathic POTS — the same patient may have positive autoantibodies AND reduced QSART/IENFD

How to Identify Your Subtype

Why Subtype Identification Matters

The clearest example of why subtype matters is the beta-blocker question. Beta-blockers are a first-line treatment for most POTS subtypes — they reduce heart rate and improve exercise tolerance. But in hyperadrenergic POTS, standard beta-blocker doses can cause a paradoxical worsening because they block beta-2 receptors (causing vasoconstriction) while leaving alpha-1 receptors unopposed, raising blood pressure and worsening symptoms.

Similarly, fludrocortisone (a volume expander) is helpful in hypovolemic POTS but can worsen hypertension in hyperadrenergic POTS. Midodrine (a vasoconstrictor) is helpful in neuropathic POTS but can cause dangerous supine hypertension in hyperadrenergic POTS.

If you have been on a POTS treatment that is not working or is making you worse, subtype testing is the most important next step.